This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Protein Sciences Corporation
Drug Names(s): ASP7374, UMN-0502, trivalent recombinant hemagglutinin vaccine
Description: UMN-0502 is a seasonal influenza vaccine manufactured by using a baculovirus to grow the three kinds of hemagglutinins in insect cells, with a combination of recombinant DNA technology, also called the Baculovirus Expression Vector System (BEVS). Like other seasonal flu viruses, the incorporated strains vary from year to year, depending on which strains the USPHS expects to be most prevalent. Flublok contains no adjuvant.
Deal Structure: FluBlok (ASP7374) was originally developed in the U.S. by Protein Sciences. It is being developed in Japan by Astellas and UMN Pharma.
UMN Pharma and PSC
In August 2006, Protein Sciences Corporation (PSC) announced that it signed an agreement with UMN Pharma licensing FluBlok for the Japan market. PSC will transfer technology to UMN which will be responsible for the registration, manufacture, marketing and sale of FluBlok in Japan. Applications include annual and pandemic use of FluBlk. After registration is achieved, UMN will buy commercial quantities of FluBlok from PSC until a commercial manufacturing facility is available in Japan. The license terms include a multimillion dollar up front payment and double digit royalties.
In November 2010, Protein Sciences Corporation (PSC) announced that it expanded its 2006 agreement with UMN in the Japan market. The amendment allows UMN to enter into collaboration agreements with Astellas and IHI Corporation (IHI). Astellas...See full deal structure in Biomedtracker
Partners: UMN Pharma, Inc. Astellas Pharma, Inc.
Additional information available to subscribers only: